Daniel E, Maguire MG, Grunwald JE, et al. - Researchers conducted this longitudinal study to determine the incidence and progression of non-geographic atrophy (NGA) and related risk factors. From January 11, 2019, through November 27, 2019, data analyses were conducted. Participants (n = 1,107) in the study were randomized to ranibizumab or bevacizumab for 2 years of monthly or as-needed injections or monthly injections for 1 year and as-needed injections the following year. Data reported that the cumulative risk of NGA was 35%, 59%, and 81% at 1-year, 2-year, and 5-year follow-ups, respectively. It was noted that the cumulative risk of progression from incident NGA in years 1 and 2 to GA was 29%, 43%, and 50% at 1, 3, and 4 years, respectively. More than half of the eyes in the study developed NGA in the location of nAMD after 2 years of protocol-guided anti–vascular endothelial growth factor treatment for nAMD. After three more years of regular care, half of them progressed to GA.